Abstract
High antibody titres against merozoite surface protein (MSP)-1 can protect against Plasmodium falciparum infection. A recent vaccine trial tested two vaccines on Aotus monkeys [Stowers, S.W. et al. (2001) Infect. Immun. 69, 1536–1546]. The first vaccine, which protected 86% of monkeys from uncontrolled parasitaemia, was based on the 42-kDa C-terminal portion of MSP-1 and was expressed as a secreted protein in baculovirus-infected insect cells. The second vaccine, based on the smaller, 19-kDa C-terminal portion of MSP-1, was expressed by the yeast Saccharomyces cerevisiae and protected only 43% of monkeys from uncontrolled parasitaemia. In each case, protection was only seen when high antibody levels were obtained by formulation of the vaccine in Freund's adjuvant, and not with an alternative adjuvant (MF59). SHK
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
